Covered recipient · General Payments record
CONOR PATRICK O'DONNELL
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
General Payments · PY2023–2024
$686.05
- Reported across 22 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $590.01 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $352.57 | 13 |
| Amgen Inc. | $188.02 | 3 |
| Acerta Pharma LLC | $25.86 | 1 |
| Janssen Biotech, Inc. | $23.56 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $26.86 | 01/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105141260 | CMS |
| ABBVIE INC. | $103.40 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105141262 | CMS |
| ABBVIE INC. | $126.17 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105141264 | CMS |
| ABBVIE INC. | $2.50 | 02/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105141266 | CMS |
| ABBVIE INC. | $1.45 | 04/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105141268 | CMS |
| ABBVIE INC. | $2.88 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105141270 | CMS |
| ABBVIE INC. | $24.87 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105141272 | CMS |
| ABBVIE INC. | $0.54 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105141274 | CMS |
| ABBVIE INC. | $16.49 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105141276 | CMS |
| ABBVIE INC. | $0.96 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105141278 | CMS |
| ABBVIE INC. | $13.38 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105141280 | CMS |
| ABBVIE INC. | $12.86 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105141282 | CMS |
| ABBVIE INC. | $20.21 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105141284 | CMS |
| Amgen Inc. | $27.94 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111664528 | CMS |
| Amgen Inc. | $137.03 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117644265 | CMS |
| Amgen Inc. | $23.05 | 06/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111664530 | CMS |
| AstraZeneca Pharmaceuticals LP | $25.86 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105708884 | CMS |
| Janssen Biotech, Inc. | $23.56 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078590322 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.